Status:
UNKNOWN
Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Conditions:
Melanoma
Radiotherapy
Eligibility:
All Genders
Brief Summary
Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Mel...
Detailed Description
Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- uveal melanoma (With/without overt metastatic disease)
Exclusion
Key Trial Info
Start Date :
January 1 1999
Trial Type :
OBSERVATIONAL
End Date :
September 1 2006
Estimated Enrollment :
560 Patients enrolled
Trial Details
Trial ID
NCT00406900
Start Date
January 1 1999
End Date
September 1 2006
Last Update
December 6 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Ophthalmology, University of Munich
Munich, Germany, 80538